within Pharmacolibrary.Drugs.ATC.L;

model L01FX09
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 4.5500000000000005e-06,
    adminDuration  = 600,
    adminMass      = 1 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00346,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.00176,
    k12             = 0.689,
    k21             = 0.689
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01FX09</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Mogamulizumab is a humanized monoclonal antibody targeting the CC chemokine receptor 4 (CCR4), used in the treatment of certain hematological malignancies such as relapsed or refractory adult T-cell leukemia/lymphoma (ATL) and cutaneous T-cell lymphoma (CTCL). It is approved in several countries including Japan, EU, and the USA for these indications.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adult patients with CCR4-positive T-cell lymphomas (mainly CTCL and ATL); data derived from population PK analysis.</p><h4>References</h4><ol><li><p>Shimizu, Y, et al., &amp; Nakamoto, Y (2022). Development of a novel Indium-111 radiolabeled mogamulizumab targeting CCR4 for imaging adult T-cell leukemia/lymphoma in vivo. <i>Annals of nuclear medicine</i> 36(3) 319–326. DOI:<a href=&quot;https://doi.org/10.1007/s12149-021-01706-4&quot;>10.1007/s12149-021-01706-4</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35034259/&quot;>https://pubmed.ncbi.nlm.nih.gov/35034259</a></p></li><li><p>Cohen, EEW, et al., &amp; Powell, SF (2019). A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors. <i>Journal for immunotherapy of cancer</i> 7(1) 342–None. DOI:<a href=&quot;https://doi.org/10.1186/s40425-019-0815-6&quot;>10.1186/s40425-019-0815-6</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31801624/&quot;>https://pubmed.ncbi.nlm.nih.gov/31801624</a></p></li><li><p>Antoniu, SA (2010). Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma. <i>Current opinion in molecular therapeutics</i> 12(6) 770–779. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/21154168/&quot;>https://pubmed.ncbi.nlm.nih.gov/21154168</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01FX09;
